Lexaria Bioscience Corp. (LEXX) has released an update.
Lexaria Bioscience Corp. has initiated a 12-week animal study to evaluate the diabetes and weight loss effects of DehydraTECH-processed GLP-1 drugs and CBD. The study will explore the potential for improved brain absorption, weight loss, and blood sugar control. It will also assess the efficacy of combining DehydraTECH technology with CBD, and for the first time, compare their processed semaglutide and liraglutide against traditional formulations.
For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.
